Differences in gene expression between individuals with multiple primary and single primary malignancies

International Journal of Molecular Medicine

Volumn 24, Issue 5, 2009, Pages 613-622

  Stathopoulos, G P ^a   Armakolas, A ^b  

^a Errikos Dunant Hospital   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Double primary malignancies; Gene expression; Microarrays; qRT PC; Second primary tumors

Indexed keywords

BCL2 ASSOCIATED ATHANOGENE 3; CHROMOSOME 10 OPEN READING FRAME 22 PROTEIN; CHROMOSOME PROTEIN; COPPER METABOLISM DOMAIN CONTAINING 1 PROTEIN; ENHANCER OF YELLOW 2 HOMOLOG PROTEIN; F BOX PROTEIN; F BOX PROTEIN 33; GUANOSINE TRIPHOSPHATE; MITOCHONDRIAL TRANSLATIONAL RELEASE FACTOR 1 LIKE PROTEIN; PEPTIDASE; RNA; SORTING NEXIN 26 PROTEIN; START DOMAIN CONTAINING 7 PROTEIN; TUMOR PROTEIN; UBIQUITIN SPECIFIC PEPTIDASE 38 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER CELL DESTRUCTION; COLON CANCER; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE PROBE; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENOME ANALYSIS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MULTIPLE CANCER; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FOLDING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

CASE-CONTROL STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; NEOPLASMS, MULTIPLE PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 70350786141     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000272     Document Type: Article

References (51)

1. Liu YY, Chen YM, Yen SH, Tsai CM and Peng RP: Multiple primary malignancies involving lung cancer - clinical characteristics and prognosis. Lung Cancer 35: 189-194, 2002.
2. Watanabe S, Kodama T, Shimosato Y, Arimoto H, Sugimura T, Suemasu K and Shiraishi M: Multiple primary cancers in 5.456 autopsy cases in the National Cancer Center of Japan. Natl Cancer Inst 72: 1021-1027, 1984.
3. Engeland A, Bjorge T, Haldorsen T and Tretlis S: Use of multiple primary cancers to indicate associations between smoking and cancer incidence: an analysis of 500,000 cancer cases diagnosed in Norway during 1953-1993. Int J Cancer 70: 401-407, 1997.
4. Curtis RE, Boic JD, Kleinerman RA, Flannery JT and Fraumeni JF Jr: Multiple primary cancers in Connecticut and Denmark. NCI Monogr 68: 219-242, 1985.
5. Isinger A, Bhat M, Borg A and Nilbert M: CHEK2 1100 delC in patients with metachronous cancers of the breast and the colorectum. BMC Cancer 15: 6-64, 2006.
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM and Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
7. De la Chapelle A: Genetic predisposition to colorectal cancer. Natl Rev Cancer 4: 769-780, 2004.
8. Peltomaki P and Vasen H: Mutations associated with HNPCC predisposition - update of ICG - HNPCC/INSIGHT mutation database. Dis Markers 20: 269-276, 2004.
9. CHEK2 Breast Cancer Case-Control Consortium. CHEK2-1100 delC and susceptibility to breast cancer: a collaborative analysis involving 10,680 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74: 1175-1182, 2004.
10. Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT and Bottomley RH: Tumor variation in families with breast cancer. JAMA 222: 1631-1635, 1972.
11. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Möslein G, Burn J, Lynch H, Klijn J, Fodde R and Schutte M: The CHEK2 1100 delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72: 1308-1314, 2003.
12. Brison O: Gene amplification and tumor progression. Biochim Biophys Acta 1155: 25-41, 1993.
13. Richard F, Pacyna-Gengelbach M, Schlüns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I and Schwendel A: Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89: 305-310, 2000.
14. Climent J, Martinez-Climent JA, Blesa D, Garcia-Barchino MJ, Saez R, Sánchez-Izquierdo D, Azagra P, Lluch A and Garcia-Conde J: Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin Cancer Res 8: 3863-3869, 2002.
15. Verhoeven E, Mooi WJ and Michalides RJ: Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7: 355-361, 1992.
16. Bärlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi OP and Kallioniemi A: Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 60: 5340-5344, 2000.
17. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S and Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes of loci and p53 mutations. Cancer Res 60: 1077-1083, 2000.
18. Bärlund M, Monni O, Weaver JD, Kauraniemi P, Sauter G, Heiskanen M, Kallioniemi OP and Kallioniemi A: Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosom Cancer 35: 311-317, 2002.
19. Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S, Fritz B, Bentz M, Sinn HP, Radlwimmer B and Lichter P: Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer 65: 429-447, 2005.
20. Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P, Berghagen H, Jensen M, Kristiansen L, Moen C, Sharma P, Zaka A, Arnes J, Sauer T, Akslen LA, Schlichting E, Børresen-Dale AL and Lönneborg A: Early detection of breast cancer on gene-expression patterns in peripheral blood cells. Breast Cancer Res 7: R634-R644, 2005.
21. Gitsch G, Hanzal E, Jensen D and Hacker NF: Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 85: 504-508, 1995.
22. Pearl ML, Johnson CM, Frank TS and Roberts JA: Synchronous dual primary ovarian and endometrial carcinomas. Int J Gynaecol Obstet 42: 305-312, 1993.
23. Falkenberry SS, Steinhoff MM, Gordinier M, Rappoport S, Gajewski W and Granai CO: Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. J Reprod Med 41: 713-718, 1996.
24. Dobbin K and Simon R: Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics 6: 27-38, 2005.
25. Yongming AS: http://bioconductor.org/packages/1.9/bioc/html/ ABarray.html.
26. Smyth GK and Limma: Linear models for microarray data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds). 1st edition. Springer, New York, pp397-420, 2005.
27. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics 19: 185-193, 2003.
28. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments, Statistical Applications in Genetics and Molecular Biology (SAGMB) 3 No. 1, Article 3, 2004.
29. Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B 57: 289-300, 1995.
30. Cho R and Campbell M: Transcription, genomes, function. Trends Genet 16: 409-415, 2000.
31. Cortes C and Vapnik V: Support-vector network Machine Learning 20: 1-25, 1995.
32. Robert, C. P and Casella G. Monte Carlo Statistical Methods (2nd ed). Springer, New York, 2004.
33. Du X, Nagata S, Ise T, Stetler-Stevenson M and Pastan I: FCRL1 on chronic lymphocyte leukemia, hairy cell leukemia and B cell non Hodgkin lymphoma as a target of immunotoxins. Blood 111: 338-342, 2008.
34. Malek SN, Dordai DI, Reim J, Dintzis H and Desiderio S: Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci USA 95: 7351-7356, 1998.
35. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW and Jelinek DF: Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clinc Invest 118: 306-315, 2008.
36. Vitek L and Schwertner HA: The Heme catabolic pathway and its protective effects on oxidative stress mediated diseases. Adv Clin Chem 42: 1-57, 2007.
37. Mani A and Gelmann EP: The Ubiquitin-Proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789, 2005.
38. Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, Copland JA and Anastasiadis PZ: p120 catenin isoform switch affects Rho activity, induces tumor cell invasion and predicts metastatic disease. J Biol Chem 283: 18344-18354, 2008.
39. Jeon TJ, Lee DJ, Lee S, Weeks G and Firtel RA: Regulation of Rap1 activity by RapGAP1 controls cell adhesion at the front of chemotaxing cells. J Cell Biol 179: 833-842, 2007.
40. Pastorekova S, Zatovicova M and Pastorek J: Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 14: 685-698, 2008.
41. Small D, Levenstein M and Kim E: STK-1, the human homolog of Flk-2/ Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Nat Acad Sci USA 91: 459-463, 1994.
42. Watanabe H, Shionyu M, Kimura T, Kimata K and Watanabe H: Splicing factor 3b subunit 4 binds BMPR-IA and inhibits osteochondral cell differentiation. J Biol Chem 282: 20728-20738, 2007.
43. Angeletti S, Rena V, Nores R, Fretes R, Panzetta-Dutari GM and Genti-Raimondi S: Expression and localization of StarD7 in trophoblast cells. Placenta 29: 396-404, 2008.
44. Gentilella A, Passiatore G, Deshmane S, Turco MC and Khalili K: Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells. Oncogene 27: 5011-5018, 2008.
45. Iwasaki M, Homma S, Hishiya A, Dolezal SJ, Reed JC and Takayama S: BAG3 regulates motility and adhesion of epithelial cancer cells. Cancer Res 67: 10252-10259, 2007.
46. Liu H, Nakazawa T, Tezuka T and Yamamoto T: Physical and functional interaction of Fyn Ttyrosine kinase with a brain-enriched Rho GTPase-activating protein TCGAP. J Biol Chem 281: 23611-23619, 2006.
47. Zucchi I, Mento E, Kuznetsov VA, Scotti M, Valsecchi V, Simionati B, Vicinanza E, Valle G, Pilotti S, Reinbold R, Vezzoni P, Albertini A and Dulbecco R: Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Nat Acad Sci USA 101: 18147-18152, 2004.
48. Adachi Y, Pavlakis GN and Copeland TD: Identification and characterization of SET a nuclear phosphoprotein encoded by the translocation break point in acute adifferentiated leukaemia. J Biol Chem 269: 2258-2262, 1994.
49. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N and Bachs O: The SET protein regulates G2/M transition by modulating cyclin B-cyclin dependent kinase 1 activity. J Biol Chem 278: 1158-1164, 2003.
50. Ozbek U, Kandilci A, van Baal S, Bonten J, Boyd K, Franken P, Fodde R and Grosveld GC: SET-CAN the product of t(9;9) in acute undifferentiated leukaemia, causes expansion of early haematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol 171: 654-666, 2007.
51. Ralph S, Brenchley PE, Summers A, Rosa DD, Swindell R and Jayson GC: Heparenase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Sci 98: 844-849, 2007.